|
FEATURED
Young patients with multiple myeloma (MM) often receive high-dose therapy with autologous stem-cell transplantation (ASCT). Residual disease in evitably leads to relapse, and a research aim has been to determine ways to prevent this. In 2 phase 3 studies, maintenance therapy with lenalidomide resulted in a doubling of the time to disease progression. Read more.
|